Collaborators

Surgical Oncology Laboratory – the folate research experts

Surgical Oncology Laboratory, SOL, (formerly a surgeon-oncology laboratory) at the Östra Hospital in Gothenburg, conducts research in surgery and oncology. SOL has internationally recognised experience of research on folates, especially within colorectal cancer and folates with excellence in molecular biology. Isofol’s founder, Professor Bengt Gustavsson, also founded SOL.

Merck & Cie – experts in the processing of substance

Merck & CIE is a subsidiary of Merck KGaA, Germany, with which Isofol has a strategic research and development partnership. The partnership, formalized in a global license agreement offers many synergies in which Isofol has specialised knowledge in the use of arfolitixorin for cancer treatment, and Merck has knowledge of synthesising a stable API (active pharmaceutical ingredient) of [6R]-MTHF and formulation of a stable and durable drug (arfolitixorin). Through a global licensing agreement with Merck KGaA, Germany, Isofol has the exclusive right to develop and commercialise arfolitixorin for oncology. The license agreement with Merck also gives Isofol access to the unique patent-protected manufacturing process of arfolitixorin.

Charité-Universitätsmedizin

Isofol has a collaboration agreement with Charité-Universitätsmedizin in Berlin, Germany, and the Department of Hematology, Oncology, and Cancer Immunology (CCM), led by Prof. Dr. med. Sebastian Stintzing. The collaboration encompasses the development program for the drug candidate arfolitixorin for colorectal cancer and other solid tumors. Within the framework of the collaboration, Isofol and Charité-Universitätsmedizin will discuss issues relevant to the clinical phase I/II study such as inclusion criteria, patient population, and statistical methods, as well as putting in place a clinical trial agreement where Prof. Dr. med. Stintzing will take the role of the study’s coordinating investigator.

Patent experts

Isofol works continuously to patent protect the intellectual property rights for the company’s drug candidate, arfolitixorin. This takes place in a structured way through close collaboration with internal and external experts, both nationally and internationally.

Regulatory issues

Through well-established collaboration NDA Group in Europe, Isofol receives valuable support in interactions with regulatory authorities.